A patientcentric approach can we simplify the use

A patient-centric approach – can we simplify the use of anti-diabetic treatments? John Buse School of Medicine, University of North Carolina, USA

IDeg. Lira is not marketed in Spain Agenda • Common barriers to insulin therapy: • Hypoglycaemia • Weight gain • Regimen complexity • GI adverse events in patients treated with IDeg. Lira • Patient-reported outcomes in IDeg. Lira clinical trials • Real-world studies of IDeg. Lira GI, gastrointestinal

IDeg. Lira is not marketed in Spain IDeg. Lira demonstrated significant improvements in Hb. A 1 c across the DUAL programme End-of-treatment Hb. A 1 c (%) DUAL I ext. 8. 3 -1. 8* 6. 4 DUAL IV 7. 9 1 WT 8. 2 -1. 5* -2. 0* 6. 4 6. 1 DUAL VI 2 WT DUAL VIII† DUAL IX 8. 1 8. 5 8. 2 -2. 0* -1. 8* -1. 9* 6. 0 6. 4 6. 3 Add to OAD(s) DUAL III 7. 8 DUAL II 8. 7 -1. 9* -1. 3* 6. 4 GLP-1 switch 6. 9 DUAL VII 8. 4 8. 2 -1. 8* -1. 5* 6. 6 6. 7 Basal insulin switch Across all nine studies, IDeg. Lira decreased mean Hb. A 1 c to below 7. 0% (6. 0– 6. 9%) *Mean change in Hb. A 1 c from baseline to end of trial; †Hb. A 1 c reduction for patients that remained on IDeg. Lira at Week 104 (n=333) GLP-1 RA, glucagon-like peptide-1 receptor agonist; IAsp; insulin aspart; IDeg. Lira, insulin degludec/liraglutide; IGlar U 100, insulin glargine U 100; OAD, oral anti-diabetic drug Gough et al. Diabetes Obes Metab 2015; 17: 965– 73 ; Buse et al. Diabetes Care 2014; 37: 2926– 2933 ; Linjawi et al. Diabetes Ther 2017; 8: 101– 114; Rodbard et al. Diabet Med 2017; 34: 189– 196; Lingvay et al. JAMA 2016; 315: 898– 907; Harris et al. Diabetes Obes Metab 2017; 19: 858– 865; Billings et al. Diabetes Care 2018; 41: 1009– 1016; Aroda et al. Lancet Diabetes Endocrinol 2019; 7: 596– 605; Philis-Tsimikas et al. Diabetes Obes Metab 2019; 21: 3199– 1408

IDeg. Lira is not marketed in Spain Common barriers to insulin initiation and intensification Hypoglycaemia 1 Weight gain 2 Complexity 1 More than half of T 2 D patients on basal insulin are not at target Hb. A 1 c 3 T 2 D, type 2 diabetes 1. Peyrot et al. Diabet Med 2012; 29: 682– 689; 2. Carver C. Diabetes Educ 2006; 32: 910– 917 ; 3. Giugliano et al. Diab Care. 2011; 34: 510– 517

IDeg. Lira is not marketed in Spain Common barriers to insulin initiation and intensification Hypoglycaemia 1 Weight gain 2 Complexity 1 More than half of T 2 D patients on basal insulin are not at target Hb. A 1 c 3 T 2 D, type 2 diabetes 1. Peyrot et al. Diabet Med 2012; 29: 682– 689; 2. Carver C. Diabetes Educ 2006; 32: 910– 917 ; 3. Giugliano et al. Diab Care. 2011; 34: 510– 517

IDeg. Lira is not marketed in Spain DUAL trials Hypoglycaemia IDeg. Lira Placebo (DUAL IV) Insulin degludec (DUAL I and II) IGlar U 100 (DUAL V and IX) Liraglutide (DUAL I)/GLP-1 RA (DUAL III) IGlar U 100 + IAsp (DUAL VII) 10. 0 Rates of hypoglycaemia (events per PYE) 9. 0 8. 2 8. 0 7. 0 6. 0 5. 1 5. 0 3. 5 4. 0 3. 0 2. 0 1. 0 2. 8 1. 4 0. 2 0. 0 DUAL I ext. 0. 8 0. 2 2 WT 1 WT DUAL IV DUAL VI DUAL IV Add to OAD(s) 0. 4 2. 6 2. 2 1. 5 0. 9 1. 1 0. 1 DUAL IX DUAL III DUAL IX GLP-1 RA switch DUAL II DUAL VII Basal insulin switch 1 WT, once-weekly titration; 2 WT, twice-weekly titration; GLP-1 RA, glucagon-like peptide-1 receptor agonist; IAsp; , insulin aspart; IDeg. Lira, insulin degludec/liraglutide; IGlar U 100, insulin glargine U 100; OAD, oral anti-diabetic drug Gough et al. Diabetes Obes Metab 2015; 17: 965– 73 ; Buse et al. Diabetes Care 2014; 37: 2926– 2933 ; Linjawi et al. Diabetes Ther 2017; 8: 101– 114; Rodbard et al. Diabet Med 2017; 34: 189– 196; Lingvay et al. JAMA 2016; 315: 898– 907 ; Harris et al. Diabetes Obes Metab 2017; 19: 858– 865; Billings et al. Diabetes Care 2018; 41: 1009– 1016; Philis-Tsimikas et al. Diabetes Obes Metab 2019; 21: 3199– 1408

IDeg. Lira is not marketed in Spain Common barriers to insulin initiation and intensification Hypoglycaemia 1 Weight gain 2 Complexity 1 More than half of T 2 D patients on basal insulin are not at target Hb. A 1 c 3 T 2 D, type 2 diabetes 1. Peyrot et al. Diabet Med 2012; 29: 682– 689; 2. Carver C. Diabetes Educ 2006; 32: 910– 917 ; 3. Giugliano et al. Diab Care. 2011; 34: 510– 517

IDeg. Lira is not marketed in Spain DUAL trials Body weight IDeg. Lira Placebo (DUAL IV) Insulin degludec (DUAL I and II) IGlar U 100 (DUAL V and IX) Liraglutide (DUAL I)/GLP-1 RA (DUAL III) IGlar U 100 + IAsp (DUAL VII) Change in body weight (kg) 4. 0 3. 0 2. 3 2. 0 2. 6 2. 0 1. 8 0. 5 1. 0 0. 0 -1. 0 -0. 1 -0. 4 -1. 0 -2. 0 -3. 0 -4. 0 -5. 0 -0. 8 -1. 0 -1. 4 -2. 0 -0. 9 -2. 7 -3. 0 2 WT 1 WT DUAL I ext. DUAL IV DUAL VI Add to OAD(s) DUAL IX DUAL III GLP-1 RA switch DUAL II DUAL VII Basal insulin switch 1 WT, once-weekly titration; 2 WT, twice-weekly titration; GLP-1 RA, glucagon-like peptide-1 receptor agonist; IAsp; , insulin aspart; IDeg. Lira, insulin degludec/liraglutide; IGlar U 100, insulin glargine U 100; OAD, oral anti-diabetic drug Gough et al. Diabetes Obes Metab 2015; 17: 965– 73 ; Buse et al. Diabetes Care 2014; 37: 2926– 2933 ; Linjawi et al. Diabetes Ther 2017; 8: 101– 114; Rodbard et al. Diabet Med 2017; 34: 189– 196; Lingvay et al. JAMA 2016; 315: 898– 907 ; Harris et al. Diabetes Obes Metab 2017; 19: 858– 865; Billings et al. Diabetes Care 2018; 41: 1009– 1016; Philis-Tsimikas et al. Diabetes Obes Metab 2019; 21: 3199– 1408

IDeg. Lira is not marketed in Spain Common barriers to insulin initiation and intensification Hypoglycaemia 1 Weight gain 2 Complexity 1 More than half of T 2 D patients on basal insulin are not at target Hb. A 1 c 3 T 2 D, type 2 diabetes 1. Peyrot et al. Diabet Med 2012; 29: 682– 689; 2. Carver C. Diabetes Educ 2006; 32: 910– 917 ; 3. Giugliano et al. Diab Care. 2011; 34: 510– 517

IDeg. Lira is not marketed in Spain DUAL VII Trial design IDeg. Lira + metformin (n=252) Patients with T 2 D (N=506) IGlar U 100 + IAsp (≤ 4 times) + metformin (n=254) 0 pen 1 injection 1 SMBG test 2 26 IDeg. Lira T W T F S Daily regimen pens 1 Daily regimen M 2 2 -5 Basal–bolus S injections 2 SMBG test 2 Number of injections and SMBG tests are based on the number of meals IAsp, insulin aspart; IDeg. Lira, insulin degludec/liraglutide; IGlar U 100, insulin glargine 100 units/m. L; SMBG, self-monitored blood glucose; T 2 D, type 2 diabetes 1. Billings et al. Diabetes Care 2018; 41: 1009– 1016; 2. Owens et al. Diabetes Prim Care 2004; 6: 8– 16 BREAKFAST – 2 LUNCH 1 1 1 End of trial 1: 1 Randomisation EVENING DINNER Screening Week Trial information: Open label Non-inferiority Treat-to-target M T W T F S S

IDeg. Lira is not marketed in Spain DUAL VII Hb. A 1 c over time 8. 5 IGlar U 100 + IAsp (n=254) 8. 0 8 64 7. 5 58 7. 0 7 53 6. 5 48 6. 0 42 6 5. 5 0. 0 5. 5 0 ∆Hb. A 1 c (%) 0 2 4 6 8 10 12 14 Time (weeks) 16 18 20 22 24 IDeg. Lira IGlar U 100 + IAsp ETD [95% CI] – 1. 49 – 1. 48 − 0. 02 [– 0. 16; 0. 12] p<0. 0001 for test of non-inferiority by 0. 3% ETD is based on LSMeans from full analysis set, using mixed model for repeated measurement. The dashed lines denote the ADA/EASD Hb. A 1 c target <7. 0% and AACE Hb. A 1 c ≤ 6. 5% CI, confidence interval; ETD, estimated treatment difference; IAsp, insulin aspart; IDeg. Lira, insulin degludec/liraglutide; IGlar U 100, insulin glargine 100 units/m. L; LSMean, least squares mean Figure sourced from: Billings et al. Diabetes Care 2018; 41: 1009– 1016 (Figure 2 A); Billings et al. Diabetes 2017; 66(Suppl. 1): A 36 26 Hb. A 1 c (mmol/mol) Hb. A 1 c (%) 69 8. 5 IDeg. Lira (n=252)

IDeg. Lira is not marketed in Spain DUAL VII Key clinical findings 0. 0 -0. 5 -1. 0 -1. 5 -2. 0 -1. 48 -1. 46 ETD: – 0. 02% [– 0. 16; 0. 12] 95% CI, p<0. 0001 for non-inferiority * Baseline Hb. A 1 c 8. 2% EOT Hb. A 1 c 6. 7% IDeg. Lira IGlar U 100 + IAsp 3 2. 64 2 1 0 -1 -2 -0. 93 ETD: – 3. 57 kg [– 4. 19; – 2. 95] 95% CI, p<0. 0001 Hypoglycaemia rate (episodes/yr) IGlar U 100 + IAsp Change in body weight (kg) Change in Hb. A 1 c (%) IDeg. Lira Confirmed hypoglycaemia† Weight Hb. A 1 c 10 ERR: 0. 11 [0. 08; 0. 17] 95% CI, p<0. 0001 8 8. 17 6 4 2 1. 07 0 IDeg. Lira IGlar U 100 + IAsp *Test against non-inferiority limit of 0. 3%; †Severe or BG-confirmed symptomatic: an episode that is severe according to the ADA classification or BG-confirmed by a plasma glucose value <3. 1 mmol/L (<56 mg/d. L) with symptoms consistent with hypoglycaemia CI, confidence interval; EOT, end of trial; ETD, estimated treatment difference; ERR, estimated rate ratio; IAsp, insulin aspart; IGlar U 100, insulin glargine U 100; PYE, patient-years of exposure Billings et al. Diabetes Care 2018; 41: 1009– 1016

IDeg. Lira is not marketed in Spain DUAL VII Percentage of patients receiving 0, 1, 2 or ≥ 3 bolus injections at Week 26 (BB arm) 7. 8% Number of bolus injections 0 (n=3) 24. 3% 1 (n=18) 2 (n=56) ≥ 3 (n=153) ≥ ≥ 67% of patients required ≥ 3 and 24% of patients required 2 bolus injections Each bolus injection required an SMBG reading and a decision regarding the dose Data are based on the full analysis set. BB, basal–bolus; IDeg. Lira, insulin degludec/liraglutide; SMBG, self-monitored blood glucose Miller et al. Diabetes Obes Metab 2019; doi: 10. 1111/dom. 13851

IDeg. Lira is not marketed in Spain Impact of multiple daily injections Patients perception of treatment burden versus number of daily injections from a self-administered, mailed survey 6 5 Perceived 4 burden (0 to 6) 3 3. 5 3. 9 4. 4 4. 8 2 1 0 + Insulin once daily †The scale ranges from 0 (do not dislike at all) to 6 (dislike very much) Adapted from Vijan et al. J Gen Intern Med 2005; 20: 479– 482 Insulin twice daily Insulin twice + 3 SMBGs daily Insulin 3– 4 times daily

IDeg. Lira is not marketed in Spain DUAL VII Number of insulin dose adjustments required during 26 weeks of treatment IDeg. Lira IGlar U 100 + IAsp 350 (n=252) (n=253) 300 250 Mean (SD) number of insulin dose adjustments during trial 200. 1 200 150 100 50 16. 6 17. 1 0 0 Basal insulin Bolus insulin There were a similar number of basal dose adjustments in patients treated with IDeg. Lira vs IGlar U 100, despite IDeg. Lira being initiated at 16 U, whereas IGlar U 100 was titrated from the pre-trial basal dose (mean 33 U) Data are mean (SD) based on the safety analysis set. IAsp, insulin aspart; IDeg. Lira, insulin degludec/liraglutide; IGlar U 100, insulin glargine 100 units/m. L; SD, standard deviation Miller et al. Diabetes Obes Metab 2019; doi: 10. 1111/dom. 13851

IDeg. Lira is not marketed in Spain Insulin titration in clinical practice • Almost 50% of patients with T 2 D who start basal insulin do not achieve Hb. A 1 c targets 1 and there are several key reasons for titration inertia • A European survey of HCPs and basal insulin-treated patients found: 59% 38% of patients uncontrolled after 27 months only increased dose by <10 U since initiation 2 of patients were concerned that a dose increase means disease is getting worse 3 25% of patients were concerned about injecting too much insulin 3 HCP, healthcare professional; T 2 D, type 2 diabetes; U, units 1. Stark Casagrande et al. Diabetes Care 2013; 36: 2271– 2279 ; 2. Berard et al. EASD 2016; poster 910; Berard et al. Diabetes Obes Metab 2018; 20: 301– 308 18% of patients thought treatment is a burden/not a priority 3

IDeg. Lira is not marketed in Spain DUAL VII Total daily insulin dose over time IDeg. Lira total insulin dose (n=252) Insulin dose (units) 100 IGlar U 100 + IAsp total insulin dose (n=253) 84. 1 U BB total insulin dose 80 60 40 40. 4 U IDeg. Lira total insulin dose 20 ETD: – 44. 50 U [– 48. 30; – 40. 71]95% CI p<0. 0001 0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 Time (weeks) ETD is based on observed data using MMRM with treatment, region and visit as factors and insulin dose at screening and baseline Hb. A 1 c as covariates BB, basal–bolus; CI, confidence interval; ETD, estimated treatment difference; IAsp, insulin aspart; IDeg. Lira, insulin degludec/liraglutide; IGlar U 100, insulin glargine 100 units/m. L; MMRM, mixed model for repeated measurement; U, units Billings et al. Diabetes Care 2018; 41: 1009– 1016

IDeg. Lira is not marketed in Spain DUAL VII Basal–bolus components of insulin dose over time Insulin dose (units) 100 Bolus insulin (IAsp) component dose of BB IDeg. Lira total insulin dose (n=252) Basal insulin (IGlar U 100) component dose of BB IGlar U 100 + IAsp total insulin dose (n=253) 84. 1 U BB total insulin dose 80 60 40 40. 4 U IDeg. Lira total insulin dose 20 ETD: – 44. 50 U [– 48. 30; – 40. 71]95% CI p<0. 0001 0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 Time (weeks) ETD is based on observed data using MMRM with treatment, region and visit as factors and insulin dose at screening and baseline Hb. A 1 c as covariates BB, basal–bolus; CI, confidence interval; ETD, estimated treatment difference; IAsp, insulin aspart; IDeg. Lira, insulin degludec/liraglutide; IGlar U 100, insulin glargine 100 units/m. L; MMRM, mixed model for repeated measurement; U, units Billings et al. Diabetes Care 2018; 41: 1009– 1016

IDeg. Lira is not marketed in Spain DUAL VII Percentage of patients achieving Hb. A 1 c <7. 0% and composite endpoints Proportion of patients achieving target (%) 100 80 60 IDeg. Lira (n=252) IGlar U 100 + IAsp (n=254) Odds ratio: 0. 91 [0. 62; 1. 33]95% CI, NS 66. 0 67. 0 Odds ratio: 2. 58 [1. 78; 3. 74]95% CI* Odds ratio: 4. 46 [2. 89; 6. 89]95% CI* Odds ratio: 10. 39 [5. 76; 18. 75] 95% CI* 57. 6 40 43. 3 33. 5 20 6. 4 15. 5 0 Hb. A 1 c <7. 0%, no weight gain 38. 2 Hb. A 1 c <7. 0%, no hypoglycaemiaa and no weight gain %, Based on observed data. *Statistically significant difference (in favour of IDeg. Lira). a. Severe or BG-confirmed symptomatic hypoglycaemia was based on hypoglycaemic episodes during a patient’s last 12 weeks of treatment BG, blood glucose; CI, confidence interval; IAsp, insulin aspart; IDeg. Lira, insulin degludec/liraglutide; IGlar U 100, insulin glargine 100 units/m. L; NS, non-significant Billings et al. Diabetes Care 2018; 41: 1009– 1016

IDeg. Lira is not marketed in Spain A common concern when initiating GLP-1 RAs are GI side effects • GI side effects, particularly nausea, are the most frequently reported adverse events in patients treated with GLP-1 RAs 1, 2 • However, these side effects are generally transient, occurring mainly in the initial weeks of treatment 3 GLP-1 RA, glucagon-like peptide-1 receptor agonist; GI, gastrointestinal; IDeg. Lira, insulin degludec/liraglutide 1. Nauck et al. Diabetes Care 2009; 32: 84– 90; 2. Balena et al. Diabetes Obes Metab 2013; 15: 485– 502; 3. Garber. Diabetes Care 2011; 34(Suppl. 2): S 279–S 284

IDeg. Lira is not marketed in Spain DUAL I ext. , II and III 12 10 8 6 4 2 0 Week 0 Open label IDeg. Lira (n=825) Degludec (n=412) Liraglutide (n=412) 12 16 DUAL II 2 Double blind IDeg. Lira (n=199) Degludec (n=199) 4 8 12 16 20 20 24 28 12 10 8 6 4 2 0 Week 0 32 36 40 44 48 IDeg. Lira (n=291) GLP-1 RA (n=145) 4 8 GLP-1 RA, glucagon-like peptide-1 receptor agonist; IDeg. Lira, insulin degludec/liraglutide; OAD, oral anti-diabetic drug 1. Gough et al. Diabetes Obes Metab 2015; 17: 965– 73 ; 2. Buse et al. Diabetes Care 2014; 37: 2926– 2933 ; 3. Linjawi et al. Diabetes Ther 2017; 8: 101– 114 12 16 20 52 Open label DUAL III 3 Patients (%) 8 After GLP-1 RA 4 Patients (%) 12 10 8 6 4 2 0 Week 0 After insulin DUAL I extension 1 Patients (%) After OAD Nausea 24 28

IDeg. Lira is not marketed in Spain What about patient-reported outcomes across the DUAL programme? Change in score from baseline TRIM-D total score in DUAL III, V, VII, IX 10 IDeg. Lira vs unchanged GLP-1 RA 1 IDeg. Lira vs IGlar U 1002 ETD: 5. 0 [2. 9; 7. 2]95%CI, p<0. 001 ETD: 2. 8 [0. 9; 4. 7]95%CI, p=0. 003 IDeg. Lira vs basal–bolus therapy 3 ETD: 6. 5 [4. 4; 8. 6]95%CI, p<0. 0001 IDeg. Lira + SGLT 2 i vs IGlar U 100 + SGLT 2 i 4 ETD: 2. 8 [0. 8; 4. 7]95%CI, p=0. 0052 8 6 4 2 0 Baseline score 73. 6 IDeg. Lira 75. 0 74. 6 73. 6 72. 9 70. 9 75. 8 75. 3 GLP-1 RA IDeg. Lira IGlar U 100 IDeg. Lira Basal–bolus IDeg. Lira IGlar U 100 CI, confidence interval; ETD, estimated treatment difference; GLP-1 RA, glucagon-like peptide-1 receptor agonist; IDeg. Lira, insulin degludec/liraglutide; IGlar U 100, insulin glargine 100 units/m. L; TRIM-D, Treatment. Related Impact Measure–Diabetes 1. Linjawi et al. Diabetes Ther 2017; 8: 101– 114; 2. Lingvay et al. JAMA 2016; 315: 898– 907 ; 3. Miller et al. Diabetes Obes Metab 2019; doi: 10. 1111/dom. 13851; 4. Brod et al. ADA 2018; Poster 101 -LB

IDeg. Lira is not marketed in Spain Real-world evidence with IDeg. Lira EXTRA study design Patients with T 2 D from 61 clinics in 5 countries (N=611) Retrospective data extraction On glucoselowering drugs ≥ 6 months IDeg. Lira ± other diabetic medication (or other post-switch therapy) Baseline† Inclusion criteria • • • T 2 D ≥ 18 years Minimum data available: Hb. A 1 c at baseline and 6 months post-switch 6 months before initiation IDeg. Lira initiation 3 months ± 45 days 6 months ± 45 days 9 months ± 45 days 12 months ± 45 days Data extraction * • Statistical analyses on all safety and effectiveness outcomes were conducted on the EAS (all patients who continued IDeg. Lira treatment for ≥ 6 months, n =566) *Where data available at 3 -, 9 - and 12 -month time points. †Baseline values were defined as the most recent values during the 6 -month period before first prescription of IDeg. Lira Participants were from Germany, UK, Sweden, Austria and Switzerland EAS, effectiveness analysis set Price et al. Diabetes Obes Metab. 2018; 20: 954– 962

IDeg. Lira is not marketed in Spain Real-world evidence with IDeg. Lira EXTRA: change in Hb. A 1 c from baseline to 6 months 9. 5 8. 9% Hb. A 1 c (%) 9. 0 8. 5 8. 6% 8. 4% -1. 6%* 8. 0 -0. 9%* -1. 0%* 7. 5% 7. 3% 8. 3% -0. 9%* -0. 7%* -0. 6%* 7. 6% Insulin MDI ±OAD (n=153) Insulin + GLP 1 RA ±OAD (n=135) 7. 4% 7. 0 6. 5 0. 0 Overall (n=566) Non-injectable therapy (n=112) GLP-1 RA ±OAD (n=57) Basal ±OAD (n=109) *p<0. 0001. Data based on effectiveness analysis set (EAS) - all patients included in the FAS and having continued IDeg. Lira treatment for at least 6 months after initiation and with at least one measurement of Hb. A 1 c at 6 months (± 45 days). Significance assessed using a two-tailed paired t-test GLP-1 RA, glucagon like peptide-1 receptor agonist; MDI, multiple dose insulin injection; n, number of patients with data at both time points; OAD, oral anti-diabetic drugs Price et al. Diabetes Obes Metab 2018; 20: 954– 962

IDeg. Lira is not marketed in Spain Real-world evidence with IDeg. Lira Persistence in Sweden Persistency* of IDeg. Lira at 6 months 90 80 70 60 50 40 30 20 94% n=2281 84% of patients were persistent at 12 months† Persistent Non-persistent 9. 0 6% n=151 Change in Hb. A 1 c (%) Percentage of patients (%) 100 Change in Hb. A 1 c 6 months after initiating treatment with IDeg. Lira – 0. 5 p<0. 07 – 0. 9 8. 5 p<0. 001 8. 0 8. 5 8. 1 7. 5 Persistent (n=919) Non-persistent (n=62) 7. 0 10 0 6. 5 0. 0 0 10 20 *Patients who collected IDeg. Lira from a pharmacy at least one more time within 6 months after the first collection (index date) and were defined as having 6 -month persistency. †Patients who collected IDeg. Lira from a pharmacy at least one more time within 6 months after the index date, and at least one more time between the 6 and 12 months after initiation, and were defined as having 12 -month persistency IDeg. Lira, insulin degludec/liraglutide; RWE, real-world evidence. Eliasson et al. Diabetes 2019; 68(Supplement 1) 1110 -P

IDeg. Lira is not marketed in Spain IDeg. Lira improves patient outcomes In DUAL I–IX, IDeg. Lira decreased mean Hb. A 1 c to below 7. 0% (6. 0– 6. 9%) IDeg. Lira provided a weight benefit, low risk of hypoglycaemia and low risk of GI adverse events Hb. A 1 c AEs These results were achieved with once-daily injection of IDeg. Lira improved TRIM-D total scores Real-world studies demonstrate that a high percentage of patients persist with IDeg. Lira for 6 and 12 months and significantly reduce their Hb. A 1 c AE, adverse events; GI, gastrointestinal; GLP-1 RA, glucagon-like peptide-1 receptor agonist; IDeg. Lira, insulin degludec/liraglutide; TRIM-D, Treatment-Related Impact Measure–Diabetes

Hand question cards to the facilitators around you Please remember to complete the evaluation form